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ABSTRACT
Background: Tumour angiogenesis is modulated on both an epigenetic and 
protein level and has potential implications for immune cell responses. However, 
the importance of related angiogenic biomarkers in cholangiocarcinoma (CCA) is 
unknown. This study assessed human CCA samples for the expression of angiogenesis-
associated microRNAs, angiopoietins (Angs) and monocytes expressing the Ang-
receptor, TIE2, with regards to prognostic significance after liver resection.
Methods: Angiogenic miRNAs were analysed in frozen samples of intrahepatic 
CCA (iCC; n = 43) and hilar CCA (HC; n = 45). Ang-1 and Ang-2, as well as TIE2-
expressing monocytes (TEMs), were detected in paraffin-embedded iCC sections (n 
= 88). MiRNA expression and the abundance of TEMs and Angs were correlated with 
clinicopathological characteristics and survival.
Results: MiR-126 was downregulated in 76.7% of all CCA samples, with 
high relative expression associated with smaller tumours and reduced lymph 
node metastasis. High Ang-1 expression was associated with less lymphangiosis 
carcinomatosa and better histological grading (all p < 0.05). The absence of TEMs in 
iCC correlated with elevated CA19-9 levels. High relative miR-126 and low miR-128 
levels were associated with improved survival in iCC and HC, respectively (all p < 
0.05). High miR-126, low miR-128 and TEMs were independent prognostic factors for 
recurrence-free and overall survival (all p < 0.05).
Conclusions: These results suggest that angiogenic miRNAs, Angs and TEMs 
are of prognostic value in CCA. In addition to the possible functional links between 
angiogenic miRNA expression profiles, Angs and immune-cell responses by TEMs, 
these data have clinical implications as novel diagnostic tools.
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INTRODUCTION
MicroRNAs (miRNAs) are a large family of 
endogenous small noncoding RNAs (19–24 nucleotides) 
that play a crucial regulatory role by binding to the 3′ 
untranslated regions of target mRNAs and blocking 
translation or initiating mRNA degradation [1, 2]. 
Accumulating evidence suggests that miRNAs regulate 
tumour proliferation, invasion, apoptosis and therapy 
resistance. MiRNAs can act as oncogenes or tumour 
suppressors depending on the target mRNAs, and they 
qualify as promising biomarkers [3–5]. Moreover, 
miRNAs are crucially involved in the processes of 
vascular development and remodelling and angiopoietin 
axis-dependent tumour angiogenesis [6–8].
Recent research revealed that mature vessels express 
high levels of miR-126, which promotes the remodelling 
and stabilisation effects of angiopoietin-1 (Ang-1) [9]. 
Another angiogenic miRNA, miR-128, which is related to 
vascular endothelial growth factor (VEGF)-C translation 
and protein expression, is differentially expressed in several 
types of human cancer and impacts cancer cell growth 
and invasion. However, the published data is inconsistent 
with regards to the possible beneficial or negative impacts 
of these angiogenic miRNAs in the promotion of human 
malignancies [10–12]. In poorly vascularised human 
cholangiocarcinoma (CCA), the role of miR-128, miR-126 
and other angiogenesis-related miRNAs remains unknown.
Ang family members and VEGF are potent 
growth factors and important modulators of tumour-
related angiogenesis; however, they could also represent 
functional antagonists [13]. VEGF is required for the 
formation of the initial vascular plexus in the early phases 
of development, whilst Ang-1 is necessary for subsequent 
vascular remodelling into mature blood vessels [14]. In 
addition, VEGF can cause vascular instability by promoting 
permeability and tissue oedema, whilst Ang-1 stabilises 
existing vessels and decreases vascular leakage [15, 
16]. Recent studies highlighted the additional beneficial 
roles of Ang-1 in cancer models [17–19]. In contrast, the 
overexpression of angiopoietin-2 (Ang-2) was associated 
with an advanced disease state and poor prognosis in 
different solid malignancies, thus suggesting differential 
roles of Ang-1 and Ang-2 in tumour biology [20–22].
Tie2-expressing monocytes (TEMs) were recently 
shown to exert profound proangiogenic activities and 
constitute preeminent immunological compounds that were 
distinct from tumour-associated macrophages (TAMs) 
[23–24]. The tyrosine kinase with Ig and EGF homology 
domains 2 (TIE2) is a receptor binding to all known Angs. 
TEMs express functional TIE2 receptor and respond 
directly to Angs activity. These immune cells foster tumour 
angiogenesis and progression in various models of animal 
and human cancer [25–27]. However, as is already apparent 
for TAMs, data also imply that TEMs have a beneficial 
impact in human malignancies [28]. These effects possibly 
depend on the vascularisation grade of solid tumours and 
the associated molecular angiogenic pathways.
Angiogenic miRNAs, Angs and TEMs were 
suggested to have clinical significance in human 
malignancies where the interplay between tumour 
immunology and angiogenesis plays a central role in 
tumour progression [23]. TEMs express angiogenic 
factors such as basic fibroblast growth factor and VEGF 
and are causally involved in hepatocarcinogenesis [29]. 
In hypoxic conditions, activated endothelial cells secrete 
Angs and recruit TEMs to the tumour site, thus delineating 
the importance of the Ang–TIE2 axis and TEMs in the 
context of vascular-rich tumours, such as hepatocellular 
carcinoma (HCC) [30, 31]. However, the significance of 
these angiogenic immune markers in poorly-vascularised 
intrahepatic CCA (iCC) is unknown. It was previously 
shown that Ang-1 density was associated with beneficial 
tumour characteristics in hilar CCA (HC) and that 
corresponding TEMs positively affected patient survival 
and prognosis [28]. The current work hypothesised 
that miR-126 signalling upregulates Ang-1-dependent 
direct beneficial effects in hepatocarcinogenesis and 
indirect effects by fostering the homing of TEMs in 
tumours, which in turn exert a significant impact on 
CCA progression. Therefore the aim of the study was to 
evaluate the significance of angiogenic miRNAs, Angs 
and related TEMs at the epigenetic, protein and cellular 
level. The study also aimed to determine their association 
with tumour growth, metastasis, recurrence and clinical 
prognosis in human CCA.
RESULTS
MiRNAs regulating (lymph) angiogenic factors 
are differentially expressed in CCA
The relative expression levels of several miRNAs 
thought to regulate vascular growth factors involved in 
Ang–TIE2 signalling were initially assessed in CCA 
samples [9, 32–36]. MiR-126, miR-145, miR-128 and 
miR-107 were detected in all CCA samples. We identified 
miR-145 with highest median relative level in CCA 
when compared with adjacent noncancerous liver tissue 
(Figure 1). Of note, MiR-145 in HC revealed a strong 
up-regulation, when compared with normal tissue or 
iCC (p = 0.0128 and p = 0.0214, respectively). On the 
contrary, relative miR-107 and miR-126 expression levels 
in HC and iCC revealed a significant down-regulation, in 
comparison with normal tissue (all p ≤ 0.05; Figure 1).
MiRNA-126 is downregulated in CCA and 
associated with lymph node involvement and 
tumour growth
MiR-126 was proposed as a potent tumour 
suppressor that regulates Ang-1 signalling [9]. The relative 
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expression of miR-126 was strongly downregulated in 
32 HC subjects (71.1%) and 33 iCC subjects (76.7%). A 
strong upregulation of miR-126 was apparent in only nine 
(20.0%) HC subjects and six (13.9%) iCC subjects.
In HC, high miR-126 relative expression was 
associated with a smaller tumour mass (largest tumour 
diameter < 50 mm) (Table 1). All 27 (100%) cases with 
high relative miR-126 expression in the tumour exhibited 
a smaller tumour size. Conversely, only seven (38.8%) of 
the 18 patients with low relative miR-126 expression in 
the tumour exhibited a smaller tumour size (p = 0.0001). 
In iCC, high relative miR-126 expression was associated 
with reduced lymph node metastasis (p = 0.013). It is 
noteworthy that 13 (92.9%) of the 14 iCC patients with 
high relative miR-126 expression in the tumour showed 
no lymph node involvement.
Angiopoietin expression is associated with 
lymphangiosis carcinomatosa and histological 
grading in iCC
Ang-1 was previously shown to be associated with 
beneficial tumour characteristics in HC [31]. In the current 
work, Ang-1 distribution revealed a uniform pattern in 
all tumour areas, including the tumour-infiltrating front. 
The adjacent liver parenchyma also exhibited Ang-1 
expression; however, the pattern was less evident than in 
the tumour tissue (data not shown).
In iCC, the high density of Ang-1 in tumour 
tissue was associated with reduced lymphangiosis 
carcinomatosa. In the tumourAng1-high group, 27 (67.5%) 
of the 40 patients had no presence of lymphangiosis 
carcinomatosa. In the tumourAng1-low group, 22 (45.8%) 
of the 48 patients had no lymphangiosis carcinomatosa 
(p = 0.042). Furthermore, the high abundance of Ang-1 
in the tumour-infiltrating front correlated with a better 
histological grading. A well-differentiated (G1) tumour 
was diagnosed in 22 (84.6%) of the 26 patients in the 
invasive frontAng1-high group, while only 30 (65.2%) of the 
46 patients in the invasive frontAng1-low group revealed a G1 
tumour status (p = 0.038).
Similarly to Ang-1, Ang-2 was also uniformly dense 
in all tumour areas, including the tumour-infiltrating 
front; however, Ang-2 distribution was not significantly 
associated with clinicopathological characteristics in iCC.
TEM frequency is associated with serum levels 
of carbohydrate antigen 19-9 (CA19-9) in 
patients with iCC
In addition to angiogenic miRNAs and the 
angiopoietin axis, this study also investigated the impact 
of TEMs in CCA. In iCC, TEMs displayed a uniform 
density in the tumour, tumour-infiltrating front and 
perivascular areas. The same expression pattern was 
previously described for HC (Figure 2) [31]. Interestingly, 
Figure 1: Angiogenic micro-RNAs in hilar (HC; n = 45) and intrahepatic (iCC; n = 43) cholangiocarcinoma. The relative 
expression was calculated using the comparative ΔΔCT method, and the values were expressed as 2
-ΔCT compared to normal liver tissue. 
MiR-107 and miR-126 showed a strong downregulation in HC and iCC, compared to adjacent noncancerous liver tissue. MiR-145 in HC 
revealed a strong upregulation, when compared with normal tissue or iCC (all p<0.05).
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Table 1: Correlation of microRNA-126 relative expression in tumor with clinicopathological characteristics of 
patient with cholangiocarcinoma
Clinicopathological analysis in hilar cholangiocarcinoma
Variable miR-126 low miR-126 high P
No. of patients 18 27
Gender 0.895
 Female 8 (44.4%) 13 (46.4%)
 Male 10 (55.6%) 14 (53.6%)
Patient age, years 0.170
 ≤ 60 10 (55.6%) 20 (75.0%)
 > 60 8 (44.4%) 7 (25.0%)
Tumor size 0.0001
 ≤ 50 mm 8 (44.4%) 27 (100%)
 > 50 mm 10 (55.6%) 0  (0%)
Pathologic N stage 0.542
 Positive 7 (38.8%) 14 (51.9%)
 Negative 11 (61.2%) 13 (48.1%)
Histologic differentiation 0.798
 Well 4 (22.2%) 4 (14.8%)
 Moderate/poor 13 (77.8%) 23 (85.2%)
Clinicopathological analysis in intrahepatic cholangiocarcinoma
Variable miR-126 low miR-126 high p
No. of patients 29 14
Gender 0.676
 Female 15 (55.6%) 8 (57.1%)
 Male 14 (44.4%) 6 (42.9%)
Patient age, years 0.524
 ≤ 60 12 (41.4%) 4  (28.6%)
 > 60 17 (58.6%) 10 (71.4%)
Tumor size 0.967
 ≤ 50 mm 9 (31.0%) 4 (28.6%)
 > 50 mm 20 (69.0%) 10 (71.4%)
Pathologic N stage 0.013
 Positive 14  (47.4%) 1  (7.1%)
 Negative 15 (52.6%) 13 (92.9%)
Histologic differentiation 0.529
 Well 20 (69.0%) 9 (64.3%)
 Moderate/poor 9 (31.0%) 5 (35.7%)
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TEMs were observed in the tumour (tumourTEM-positive 
group) and tumour-infiltrating front (invasive frontTEM-
positive group) in 56 patients, while the rest of the tumour 
specimens (tumourTEM-negative group, n = 33, and invasive 
frontTEM-negative group, n = 31) displayed a complete absence 
of infiltrating TEMs. No invading TEMs were observed in 
adjacent healthy liver tissue.
The absence of TEMs in the tumour-infiltrating 
front was associated with pathological CA19-9 levels. 
In the invasive frontTEM-positive group, 43 (79.6%) of the 54 
patients had normal CA19-9 serum levels, whereas in the 
invasive frontTEM-negative group, only 15 (57.7%) of the 26 
patients had normal values (p = 0.040).
The TEM density was not significantly associated 
with other clinicopathological markers or angiopoietin 
expression in iCC; however, a trend was observed between 
reduced local and overall tumour recurrence and mitigated 
formation of fibrosis in tumours with a high TEM density 
(data not shown).
The influence of miRNAs and TEMs on overall 
and recurrence-free survival in patients with 
CCA
In iCC, survival was significantly decreased in patients 
with high relative miR-128 expression in the tumour in 
comparison to those with low miR-128 expression (p = 0.018; 
Figure 3A). The overall survival rates at 1-year postsurgery 
were 75.2% and 42.3% for patients with low and high miR-
128 tumour expression, respectively. In HC, survival was 
significantly better in patients with high relative miR-126 
expression in the tumour in comparison to those with low 
miR-126 expression (Figure 3B). No survival for longer than 
3 years after resection was observed in patients with high 
Table 2: Multivariate analysis of prognostic factors in patients with cholangiocarcinoma
Multivariate analysis (Overall Survival)
Variable Category Odds ratio p Confidence interval
Histologic 
Differentiation well or moderate/poor 2.266 0.040 1.038-4.946
T Status T2/T3 1.688 0.236 0.710-4.009
Overall Tumor 
Recurrence negative/positive 0.011 0.0001 0.001-0.093
Local Tumor 
Recurrence negative/positive 0.707 0.401 0.315-1.588
Multiple Tumor 
Nodules negative/positive 0.135 0.010 0.029-0.623
Tumor size negative/positive 0.006 0.001 0.000-0.137
TEMs in tumor negative/positive 2.423 0.040 1.042-5.633
miR-128 expression low/high 38.976 0.004 3.257-466.374
miR-126 expression low/high 0.322 0.013 0.131-0.789
Multivariate analysis (Recurrence-free Survival)
Variable Category Odds ratio p Confidence interval
Tumor Nodules solitary/multiple 0.301 0.001 0.149-0.606
Perineural Sheet 
Infiltration negative/positive 0.370 0.008 0.178-0.772
Histologic 
Differentiation well or moderate/poor 2.123 0.047 1.010-4.460
Lymph Node 
Involvement negative/positive 0.542 0.066 0.282-1.042
TEMs in tumor 
invasive front high/low 2.721 0.047 1.014-7.302
Following clinicopathological parameters were reported previously in the same cohort of patients: histologic differentiation, 
T status, overall and local tumor recurrence, multiple tumor nodules, tumor size, perineural sheet infiltration and lymph 
node involvement [37].
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miR-128 or low miR-126 expression in the tumour. Kaplan–
Meier analysis with regards to the down- or upregulation 
of miRNAs relative to adjacent normal tissue revealed no 
significant differences (data not shown).
In patients with iCC, distinct trends towards 
improved overall and recurrence-free survival after 
resection were noted in those containing TEMs; however, 
this did not reach statistical significance. The overall 
survival rates were 67.8%, 32.4% and 27.6% at 1-, 3- and 
5-years postsurgery, respectively, in patients with TEMs 
in the tumour-infiltrating front. Conversely, the overall 
survival rates were 53.1%, 20.2% and 12.8% at 1-, 3- 
and 5-years postsurgery, respectively, in patients without 
TEMs in the tumour-infiltrating front (p = 0.218) (Figure 
3C). The 1-, 3- and 5-year recurrence-free survival rates 
in patients with tumours containing TEMs were 53.1%, 
22.8% and 22.8%, respectively, whereas the 1-, 3- and 
5-year recurrence-free survival rates in patients with 
tumours without TEMs were 31.9%, 18.4% and 13.8%, 
respectively (p = 0.185; Figure 3D).
Prognostic significance of miRNAs and TEMs in 
CCA
This study also analysed whether miRNAs, Angs 
and TEMs, in addition to other clinicopathological 
parameters, could predict the outcome after resection 
for CCA. Clinicopathological parameters reported 
previously in the same cohort of patients included 
histological differentiation, T status, overall and 
local tumour recurrence, multiple tumour nodules, 
tumour size, perineural sheet infiltration and lymph 
node involvement [37]. Using multivariate analysis, 
the presence of TEMs in tumorous tissue, miR-
126 and miR-128 were all identified as independent 
prognostic factors for survival (p = 0.040, p = 0.013 
and p = 0.004, respectively; Table 2). With regards to 
recurrence-free survival, the presence of TEMs in the 
tumour-infiltrating front proved to be an independent 
prognostic variable in the multivariate analysis 
(P = 0.047; Table 2).
Figure 2: Cholangiocarcinoma stained with antibodies for CD14 and TIE2 showing a high abundance of TIE2-
expressing monocytes (TEMs) (arrow) in close proximity to blood vessels (asterisk). Original magnification: x100. Detail of 
selected area, original magnification: x400. Scale bar 50 μm.
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DISCUSSION
This study analysed the tissue density of infiltrating 
TEMs and Angs and the expression of related angiogenic 
miRNAs in tumour samples from patients who underwent 
resection for CCA. The main findings were five-fold: 
(1) a high Ang-1 density was associated with reduced 
lymphangiosis carcinomatosa and improved histological 
grading in iCC; (2) angiogenic TEMs and miRNAs were 
differentially expressed in iCC and HC; (3) associated 
with established tumour markers, tumour growth and 
lymph node involvement; (4) served as independent 
prognosticators and (5) impacted on survival rates.
In the current work we show that high miR-126 
and low miR-128 expression levels were associated with 
beneficial effects in CCA. Moreover, in accordance with 
previously published results in HC, the results showed 
that Ang-1 and TEMs correlated with improved tumour 
profiles and, together with angiogenic miRNAs, affected 
patient outcomes in CCA [28]. These findings suggest 
that ANG1–TIE2 signalling is potentially regulated by 
epigenetic miRNAs and influences TEM invasion resulting 
in beneficial effects in CCA; however, further studies are 
needed to shed light on the possible mechanisms.
Little information is currently available regarding 
the impact of angiogenesis in human CCA. Angiogenic 
miRNAs that regulate potent (lymph) angiogenic factors 
were shown to impact tumour progression in various 
models of human disease. Experimental data suggest 
a potential role of VEGF and angiopoietin-related 
pathways in CCA progression [38]. In addition, novel 
experimental and clinical research demonstrates that the 
impact of monocytes/macrophages on tumour progression 
varies with regards to the tumour type and the extent of 
neovascularization [39]. In comparison to HCC where the 
formation of prominent tumour neovascularization is a 
Figure 3: (A) Survival after intrahepatic cholangiocarcinoma surgery in relation to miR-128 expression in tumorous tissue. (B) 
Survival after hilar cholangiocarcinoma surgery in relation to miR-126 expression in tumorous tissue. (C) Survival after intrahepatic 
cholangiocarcinoma surgery in relation to the presence or absence of TEMs in the tumour-infiltrating front. (D) Recurrence-free survival 
after intrahepatic cholangiocarcinoma surgery in relation to the presence or absence of TEMs in the tumour-infiltrating front.
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major factor influencing tumour progression, the extent 
of tumour-related neovascularization in CCA is uncertain. 
Therefore the current work focused on the importance of 
angiogenic miRNAs involved in the Ang- and VEGF-
dependent molecular pathways. The next step explored 
the impact of angiogenic TEMs that directly respond to 
vascular growth factors on CCA progression and patient 
outcome.
Recent data suggest that miRNAs play important 
roles in liver biology and diseases, although the clinical 
impact of miRNAs in CCA remains to be further 
elucidated. Downregulation of miR-126 induces 
carcinogenesis, and miR-126 acts as a tumour suppressor 
and is also crucially involved in Ang-1 signalling and 
vessel maturation [9, 40–44]. Furthermore, miR-126 is 
also a potent modulator of VEGF signalling via KLF-
2-dependent mechanisms, especially in the context of 
liver inflammation and cirrhosis. This is of potential 
importance for the presented results, as CCA tumour 
progression is highly dependent upon chronic hepato-
biliary inflammation and injury [45].
Based on previous findings linking the angiopoietin 
axis to TEMs in HC, this study explored the impact 
of angiogenic miRNAs that influence Ang-1-related 
pathways on CCA progression. A potential mechanism 
was hypothesised that linked miR-126 to the activation of 
Ang-1-dependent mechanisms, which mediated enhanced 
infiltration of TEMs, which in turn exerted a beneficial 
effect on CCA progression (Figure 4). In this study, 
Ang-1 density correlated with reduced lymphangiosis 
carcinomatosa and improved histological grading. In 
addition, the multivariate analysis showed that Ang-1-
regulating miR-126 and TEMs were associated with 
improved survival and prognosis. Thus TEMs seem to 
associate with prevailing beneficial miR-126 and Ang-1 
profiles in CCA.
Figure 4: MiR-126 signalling is hypothesised to upregulate the Ang-1-dependent direct beneficial effects on tumour 
growth and indirect effects by fostering the homing TEMs in tumours, which in turn has a negative impact on CCA 
progression.
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Given the growing interest in the miRNA-
dependent modulation of (lymph) angiogenic signalling, 
the importance of other angiogenic miRNAs in CCA 
progression was investigated. Recent results are 
inconsistent; however, they do suggest that miR-
128 is involved in malignant diseases, either as a 
tumour suppressor or oncogene [10, 46–54]. A tumour 
suppressive role of miR-128 was documented for glioma, 
neuroblastoma, prostate and nonsmall cell lung cancer, 
where abnormal miR-128 expression may impact the 
malignant phenotypes of cancer cells (i.e. proliferation, 
cell motility, invasion, apoptosis and self-renewal) [54, 
55]. Conversely, in HCC and colorectal carcinoma, 
elevated serum and intratumoural levels of miR-128 were 
negatively associated with patient survival and disease 
prognosis [33].
This is the first work to document the expression 
of miR-128 in CCA. Moreover, it also shows that the 
upregulation of intratumoural miR-128 expression is a 
negative prognostic factor for patient survival following 
surgery (Table 1; Figure 3A). These data are consistent 
with studies that showed a negative prognostic value of 
elevated miR-128 serum levels in HCC patients [33]. 
However, most published scientific data showed that 
decreased miR-128 expression in tissue and serum 
samples was associated with tumour progression. This 
was linked to enhanced neovascularization via VEGF 
molecular pathways [55, 56]. The role of miR-128 in 
CCA progression is unknown. One possible explanation 
for these contradictory results is that in CCA dysregulation 
of miR-128 impacts tumour progression via mechanisms 
different from tumour related angiogenesis.
A negative prognostic value of the angiopoietin 
axis and TEMs was documented in highly vascularised 
malignancies; however, there is also a growing body 
of evidence that suggests that TEMs can have a 
positive impact. Research into HCC and pancreatic 
adenocarcinoma showed a negative influence of TEMs 
and Angs [40, 57–59]. Conversely, novel scientific data 
has linked TEMs to enhanced liver regeneration and a 
positive influence on patient outcome [60–62]. Moreover, 
Ang-1 and Ang-2 are functional antagonists, and a 
beneficial role of Ang-1 in human cancer has also been 
highlighted [17, 18].
The M1 or M2 polarisation state of TAMs 
differentially affects tumour progression and patient 
prognosis, therefore TIE2 expression on TEMs may 
be only the tip of the iceberg. In addition, further 
discrimination of distinct subpopulations within TEMs 
may deliver new insights regarding novel functions and 
differential influences on disease progression. It should be 
noted that results published to date that have revealed a 
negative prognostic value of TEMs have been performed 
in highly vascularised tumours where tumour progression 
relies on prominent tumour microvasculature [60, 63]. 
The extent of vascularisation in CCA is uncertain. In the 
current study, both Ang-1 and Ang-2 were not associated 
with the presence of TEMs; however, intratumoural Ang-
1 expression was correlated with reduced lymphangiosis 
carcinomatosa and improved histological grading. These 
findings are in accordance with previous results that 
highlighted the beneficial effects of Ang-1 and TEMs in 
HC [28].
There is a scarce amount of data available with 
respect to the clinical significance of the angiopoietin 
axis and TEMs in CCA. Previously, the significance of 
TEMs was established with respect to their circulating 
blood population [39]. However, our group was the first 
to document the importance of TEM density in cancerous 
tissue and establish a link with the angiopoietin axis in 
HC [28]. Consistent with the findings in HC, the current 
work performed intratumoural visualisation of TEMs 
using immunoreactivity and revealed their preferential 
localisation in proximity to the microvasculature (Figure 
2). Of note, a considerable number of tumours displayed a 
complete absence of TEMs.
The descriptive nature of the results is a limitation 
of the current work. Hence functional tests (i.e. in vitro 
co-culturing of TEMs and tumour-derived factors or 
tumour cells to measure and verify angiogenic responses 
will help to mechanistically elucidate the proposed effects. 
In summary, angiogenic miRNAs, the related Ang-1 axis 
and corresponding TEMs were associated with beneficial 
tumour profiles and improved outcomes in human CCA. 
However, further research is required to investigate the 
molecular mechanisms linking TEMs to miRNAs and 
related tumour angiogenesis.
MATERIALS AND METHODS
Patients and tumour samples
A total of 186 patients who underwent major 
hepatectomy for CCA (iCC or HC) at the Department of 
Surgery, Charité–Universitätsmedizin Berlin were included 
in the study. CCA was confirmed histopathologically and 
was classified according to the Union for International 
Cancer Control. The study was approved by the Ethics 
Committee of Charité–Universitätsmedizin Berlin (ID: 
111 EA1/318/15).
Clinicopathological characteristics of the study 
population were reported previously [37]. Briefly, liver 
resection was in curative intent in all patients, and none 
of the patients received neoadjuvant radiotherapy or 
chemotherapy prior to surgery. None of the patients died 
in the postoperative period. Tissue blocks containing 
embedded representative samples of the tumours were 
retrieved from the archives at the Institute of Pathology. 
Histological diagnoses of the primary tumour stage and 
nodal status were determined from haematoxylin and eosin 
stained sections. Histological evaluation of all specimens 
was performed by an independent pathologist who had 
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no knowledge of the prognosis or the clinicopathological 
variables. Cryopreserved (n = 88) and formalin-fixed 
paraffin-embedded (n = 88) tumour samples, which 
represented different patient collectives, were used. 
Analysis of miRNA expression was performed in the 
cryopreserved samples (iCC = 43; HC = 45), and Ang and 
TEM studies were performed in formalin-fixed tumour 
samples (iCC = 88).
Immunohistochemistry
All protocols used for immunohistochemistry, 
histology, cellular infiltrate quantification and angiopoietin 
density were described in detail previously [28, 37, 64, 
65].
Quantification of TEM density
Briefly, TEMs were defined by their coexpression 
of CD14 and TIE2. The TEM density in the whole 
tumour area and in the tumour-infiltrating front was 
semiquantitatively scored as 1 = negative or 2 = positive. 
For statistical analysis, a score of 1 was categorised as the 
absence of abundance (or negative), while a score of 2 was 
categorised as the presence of abundance (or positive).
Patients with iCC were divided into groups either 
by the ‘positive’ or ‘negative’ abundance of TEMs in the 
tumour (tumourTEM-positive group, n = 55, and tumourTEM-
negative group, n = 33) or by the ‘positive’ or ‘negative’ 
abundance of TEMs in the tumour-infiltrating front 
(invasive frontTEM-positive group, n = 56, and invasive 
frontTEM-negative group, n = 31). The tumour-infiltrating front 
was identified in 87 of the 88 tumour samples.
Quantification of angiopoietin density
Briefly, Angs were defined by the expression of 
Ang-1 or Ang-2. The Ang density in the whole tumour 
area was semiquantitatively classified using the following 
categories: 0 = negative, 1 = 1%–25%, 2 = 26%–75% and 
3 = >75%. For statistical analysis, scores of 0 and 1 were 
categorised as low expression, while scores of 2 and 3 
were classified as high Ang expression. Ang density in the 
tumour-infiltrating front was semiquantitatively classified 
using the following categories: 0 = negative, 1 = 1%–25%, 
2 = 26%–75% and 3 = >75%. For statistical analysis, 
scores of 0 and 1 were categorised as low abundance (or 
negative), while scores of 2 and 3 were categorised as high 
abundance (or positive).
Patients with iCC were divided into groups either 
by the ‘low’ or ‘high’ abundance of Angs in the tumour 
(tumourAng1-low group, n = 48; tumourAng2-low group, n = 66; 
tumourAng1-high group, n = 40 or tumourAng2-high group, n = 
22) or by the ‘low’ or ‘high’ abundance of Angs in the 
tumour-infiltrating front (invasive frontAng1-low group, n = 
46; invasive frontAng2-low group, n = 49; invasive frontAng1-
high group, n = 26 or invasive frontAng2-high group, n = 23). 
The tumour-infiltrating front was identified in 72 of the 88 
tumour samples stained for Ang-1 or Ang-2.
Gene expression analysis
Samples of CCA and matched adjacent 
noncancerous liver tissue were collected after liver 
resection. Samples were snap frozen, and the relative 
expression of angiogenic miRNAs (hsa-miR-107 
(MS00031255), which regulates VEGF-D signalling; 
hsa-miR-126 (MS00003430), which regulates Ang-1 
signalling; hsa-miR-128 (MS00008582), which regulates 
VEGF-C signalling and hsa-miR-145 (MS00003528), 
which regulates Ang-2 signalling) was assessed by 
quantitative reverse transcriptase PCR [9, 32–34]. Total 
RNA (including miRNA) was isolated using Qiazol® 
Lysis Reagent (Qiagen, Hilden, Germany) and purified as 
described in the user manual but with some modifications 
(miRNeasy System, Qiagen). Purified RNA was reverse 
transcribed, and qPCR was performed (miScript System 
II, Qiagen; RevertAid First Strand cDNA Synthesis Kit, 
Life Technologies, Karlsruhe, Germany and GoTaq qPCR 
Master Mix, Promega, Mannheim, Germany). RNU6 was 
used as an internal control in miRNA studies. The relative 
expression was calculated using the comparative ΔΔCT 
method, and the values were expressed as 2-ΔCT [66].
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism (Prism 6 for Macintosh Version 6.0b, GraphPad 
Software, La Jolla, CA) and SPSS software program 
(version 23). Data were described as means +/- standard 
deviations (SD) or standard error of mean (SEM, in 
figures). D’Agostino & Pearson omnibus normality test 
was used to test for normal distribution. For comparison 
of two groups unpaired t-test or non-parametric Mann-
Whitney U test was used. A Two-Way Analysis of Variance 
(Two-Way ANOVA) was performed to test whether the 
two independent variables‚ entity’ (HC versus iCC) and 
’tissue sample’ (normal tissue versus tumor) affect the 
expression of the selected miRNAs. Two-Way ANOVA was 
followed by Sidak’s multiple comparison test for a pairwise 
comparison. Survival analysis, univariate analysis and 
Kaplan–Meier curves were performed and generated using 
SPSS. Comparison of categorical and continuous variables 
was performed using the Chi-squared test and the Wilcoxon 
test, respectively. Survival data were compared using the 
log-rank test. Variables that significantly influenced survival 
in the univariate analysis were entered into a Cox regression 
analysis. When p ≤ 0.05 the differences were considered 
statistically significant.
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